Cita APA

Gadelha, M., Colao, A., Bex, M., Campigotto, F., Bartalotta, A., Maamari, R., & Raverot, G. (2019). SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study. J Endocr Soc.

Chicago Style Citation

Gadelha, Mônica, Annamaria Colao, Marie Bex, Federico Campigotto, Amy Bartalotta, Ricardo Maamari, i Gérald Raverot. "SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients With Uncontrolled Acromegaly Over Continued Treatment With First‑Generation Somatostatin Analogues (SSAs): Results From Phase 3b, Open-Label Study." J Endocr Soc 2019.

Cita MLA

Gadelha, Mônica, et al. "SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients With Uncontrolled Acromegaly Over Continued Treatment With First‑Generation Somatostatin Analogues (SSAs): Results From Phase 3b, Open-Label Study." J Endocr Soc 2019.